Gliosarcoma - Pipeline Review, H1 2017

  • ID: 4311890
  • Report
  • 187 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Agenus Inc
  • Celgene Corp
  • ERC Belgium SA
  • Merck & Co Inc
  • NewLink Genetics Corp
  • Novartis AG
  • MORE
Gliosarcoma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H1 2017, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 14, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Agenus Inc
  • Celgene Corp
  • ERC Belgium SA
  • Merck & Co Inc
  • NewLink Genetics Corp
  • Novartis AG
  • MORE
  1. Introduction
  2. Gliosarcoma - Overview
  3. Gliosarcoma - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Gliosarcoma - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Gliosarcoma - Companies Involved in Therapeutics Development
  15. Agenus Inc
  16. Bristol-Myers Squibb Company
  17. Celgene Corp
  18. DelMar Pharmaceuticals Inc
  19. ERC Belgium SA
  20. Merck & Co Inc
  21. Merrimack Pharmaceuticals Inc
  22. Millennium Pharmaceuticals Inc
  23. NewLink Genetics Corp
  24. Northwest Biotherapeutics Inc
  25. Novartis AG
  26. Nuo Therapeutics Inc
  27. Progenics Pharmaceuticals Inc
  28. Tragara Pharmaceuticals Inc
  29. Gliosarcoma - Drug Profiles
  30. ALD-451 - Drug Profile
  31. alisertib - Drug Profile
  32. avadomide hydrochloride - Drug Profile
  33. BMS-986016 - Drug Profile
  34. dasatinib - Drug Profile
  35. DCVax-L - Drug Profile
  36. dianhydrogalactitol - Drug Profile
  37. DNX-2401 - Drug Profile
  38. ERC-1671 - Drug Profile
  39. flucytosine + TBio-01 - Drug Profile
  40. G-200 - Drug Profile
  41. indoximod - Drug Profile
  42. irinotecan hydrochloride - Drug Profile
  43. irinotecan hydrochloride + TBio-02 - Drug Profile
  44. lonafarnib - Drug Profile
  45. M-032 - Drug Profile
  46. marizomib - Drug Profile
  47. p28 - Drug Profile
  48. pazopanib hydrochloride - Drug Profile
  49. pembrolizumab - Drug Profile
  50. PSMA ADC - Drug Profile
  51. RRX-001 - Drug Profile
  52. sapanisertib - Drug Profile
  53. SGT-53 - Drug Profile
  54. TG-02 - Drug Profile
  55. urelumab - Drug Profile
  56. Gliosarcoma - Dormant Projects
  57. Appendix
  58. Methodology
  59. Coverage
  60. Secondary Research
  61. Primary Research
  62. Expert Panel Validation
  63. Contact Us
  64. Disclaimer
List of Tables:
  1. Number of Products under Development for Gliosarcoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Companies, H1 2017 (Contd..1), H1
  6. Products under Development by Universities/Institutes, H1
  7. Number of Products by Stage and Target, H1
  8. Number of Products by Stage and Target, H1 2017 (Contd..1), H1
  9. Number of Products by Stage and Mechanism of Action, H1
  10. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1
  11. Number of Products by Stage and Route of Administration, H1
  12. Number of Products by Stage and Molecule Type, H1
  13. Gliosarcoma - Pipeline by Agenus Inc, H1
  14. Gliosarcoma - Pipeline by Bristol-Myers Squibb Company, H1
  15. Gliosarcoma - Pipeline by Celgene Corp, H1
  16. Gliosarcoma - Pipeline by DelMar Pharmaceuticals Inc, H1
  17. Gliosarcoma - Pipeline by ERC Belgium SA, H1
  18. Gliosarcoma - Pipeline by Merck & Co Inc, H1
  19. Gliosarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1
  20. Gliosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H1
  21. Gliosarcoma - Pipeline by NewLink Genetics Corp, H1
  22. Gliosarcoma - Pipeline by Northwest Biotherapeutics Inc, H1
  23. Gliosarcoma - Pipeline by Novartis AG, H1
  24. Gliosarcoma - Pipeline by Nuo Therapeutics Inc, H1
  25. Gliosarcoma - Pipeline by Progenics Pharmaceuticals Inc, H1
  26. Gliosarcoma - Pipeline by Tragara Pharmaceuticals Inc, H1
  27. Gliosarcoma - Dormant Projects, H1
List of Figures:
  1. Number of Products under Development for Gliosarcoma, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Top 10 Targets, H1
  4. Number of Products by Stage and Top 10 Targets, H1
  5. Number of Products by Top 10 Mechanism of Actions, H1
  6. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Agenus Inc
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • DelMar Pharmaceuticals Inc
  • ERC Belgium SA
  • Merck & Co Inc
  • Merrimack Pharmaceuticals Inc
  • Millennium Pharmaceuticals Inc
  • NewLink Genetics Corp
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Nuo Therapeutics Inc
  • Progenics Pharmaceuticals Inc
  • Tragara Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll